Chemistry:Danicamtiv

Danicamtiv
Clinical data
Other names	MYK-491
Legal status
Legal status	Investigational;
Identifiers
	IUPAC name 4-[(1R)-1-[3-(Difluoromethyl)-1-methylpyrazol-4-yl]sulfonyl-1-fluoroethyl]-N-(1,2-oxazol-3-yl)piperidine-1-carboxamide;
CAS Number	1970972-74-7;
PubChem CID	122424426;
ChemSpider	81367782;
UNII	7B2CS922HI;
KEGG	D11824;
ChEMBL	ChEMBL4594304;
Chemical and physical data
Formula	C16H20F3N5O4S
Molar mass	435.42 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES C[C@@](C1CCN(CC1)C(=O)NC2=NOC=C2)(F)S(=O)(=O)C3=CN(N=C3C(F)F)C;
	InChI InChI=1S/C16H20F3N5O4S/c1-16(19,29(26,27)11-9-23(2)21-13(11)14(17)18)10-3-6-24(7-4-10)15(25)20-12-5-8-28-22-12/h5,8-10,14H,3-4,6-7H2,1-2H3,(H,20,22,25)/t16-/m1/s1; Key:NREKKBAMVWQRES-MRXNPFEDSA-N;

Short description: Chemical compound

Danicamtiv is a cardiac myosin activator developed by Bristol Myers Squibb to treat dilated cardiomyopathy.^[1]^[2]^[3]^[4]

References

↑ Choi, Joohee; Holmes, Joshua B.; Campbell, Kenneth S.; Stelzer, Julian E. (17 October 2023). "Effect of the Novel Myotrope Danicamtiv on Cross-Bridge Behavior in Human Myocardium". Journal of the American Heart Association 12 (20): e030682. doi:10.1161/JAHA.123.030682. PMID 37804193.
↑ Shen, Shi; Sewanan, Lorenzo R.; Jacoby, Daniel L.; Campbell, Stuart G. (15 June 2021). "Danicamtiv Enhances Systolic Function and Frank-Starling Behavior at Minimal Diastolic Cost in Engineered Human Myocardium". Journal of the American Heart Association 10 (12): e020860. doi:10.1161/JAHA.121.020860. PMID 34096321.
↑ Kooiker, Kristina B.; Mohran, Saffie; Turner, Kyrah L.; Ma, Weikang; Martinson, Amy; Flint, Galina; Qi, Lin; Gao, Chengqian et al. (18 August 2023). "Danicamtiv Increases Myosin Recruitment and Alters Cross-Bridge Cycling in Cardiac Muscle". Circulation Research 133 (5): 430–443. doi:10.1161/CIRCRESAHA.123.322629. PMID 37470183.
↑ Grillo, Mark P.; Markova, Svetlana; Evanchik, Marc; Trellu, Marc; Moliner, Patricia; Brun, Priscilla; Perreard-Dumaine, Anne; Vicat, Pascale et al. (1 February 2021). "Preclinical in vitro and in vivo pharmacokinetic properties of danicamtiv, a new targeted myosin activator for the treatment of dilated cardiomyopathy". Xenobiotica 51 (2): 222–238. doi:10.1080/00498254.2020.1839982. PMID 33078965.

0.00

(0 votes)

Original source: https://en.wikipedia.org/wiki/Danicamtiv. Read more